
Sign up to save your podcasts
Or


Watch on YouTube
Andrew Catchpole, Chief Scientific Officer of hVIVO joins Martin Luke of Vox Markets to discuss hVIVO’s newly signed £6 million influenza human challenge trial contract. Andrew explains how the study will evaluate a prophylactic antiviral treatment using hVIVO’s specialist influenza challenge model, highlighting the speed and efficiency advantages of human challenge trials, the growing focus on antiviral therapies, and why hVIVO continues to attract global clients.
By Vox Markets PodcastWatch on YouTube
Andrew Catchpole, Chief Scientific Officer of hVIVO joins Martin Luke of Vox Markets to discuss hVIVO’s newly signed £6 million influenza human challenge trial contract. Andrew explains how the study will evaluate a prophylactic antiviral treatment using hVIVO’s specialist influenza challenge model, highlighting the speed and efficiency advantages of human challenge trials, the growing focus on antiviral therapies, and why hVIVO continues to attract global clients.

11 Listeners

7 Listeners

0 Listeners

13 Listeners

1 Listeners

4 Listeners

39 Listeners

8 Listeners

51 Listeners

54 Listeners

194 Listeners

38 Listeners

0 Listeners

0 Listeners

84 Listeners